Assessment of the effects of age and joint disease on hydroxyproline and glycosaminoglycan concentrations in synovial fluid from the metacarpophalangeal joint of horses.

The research study investigates how age and joint disease influence the concentration of hydroxyproline and glycosaminoglycan (GAG) in the synovial fluid found in the metacarpophalangeal joint of horses. It found that changes in hydroxyproline levels within the synovial fluid could indicate damage to the cartilage, but GAG concentration was less useful as a marker for joint disease in horses.

Overview of the Study

• The study focused on assessing the concentrations of hydroxyproline and glycosaminoglycan (GAG), and their association with osteoarthritis severity and matrix metalloproteinase (MMP) activity in horse joints.
• The researchers collected synovial fluid from the metacarpophalangeal joints of foals at different ages (birth, 5-month-old, and 11-month-old) and adult horses.
• The measured hydroxyproline and GAG concentrations provided insights into the molecular changes connected with the development and maturity of joints, and the onset of joint diseases in horses.

Methods

• The severity of joint disease in adult horses was quantified using a cartilage degeneration index (CDI) and assessing general MMP activity.
• Hydroxyproline and GAG concentrations were determined in synovial fluid samples.

Results and Conclusions

• The study found that hydroxyproline and GAG concentrations were highest in newly born foals and decreased with age, reaching a consistent level in adults by 4 years and remaining constant in healthy joints.
• In joints affected by osteoarthritis, the concentrations of hydroxyproline and GAG did not increase compared to unaffected joints.
• The results showed that hydroxyproline was significantly correlated with both the CDI and general MMP activity, indicating that changes in synovial fluid hydroxyproline concentration could signify damage to the joint’s cartilage.
• In contrast, there was no significant correlation between GAG concentration and CDI value or MMP activity, suggesting that GAG concentration may not be a reliable biomarker for monitoring equine joint disease.